| Brian J Cohen, MD | |
|
750 Washington St, Boston, MA 02111-1526 | |
| (617) 636-5000 | |
| Not Available |
| Full Name | Brian J Cohen |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 46 Years |
| Location | 750 Washington St, Boston, Massachusetts |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1326070954 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RN0300X | Internal Medicine - Nephrology | 52442 (Massachusetts) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Tufts Medical Center | Boston, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Pratt Medical Group Inc | 3375515661 | 265 |
News Archive
Use of the targeted agent pacritinib significantly reduced the symptoms and burden of advanced myelofibrosis in patients, says a Mayo Clinic researcher who co-led PERSIST-1, the worldwide phase III clinical trial that tested the therapy. Specifically, pacritinib substantially reduced severe enlargement of the spleen, a typical feature of advanced myelofibrosis, in more than 20 percent of patients and alleviated debilitating side effects in more than 46 percent.
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced positive, statistically significant data from the Company's Phase 1 clinical trial evaluating the safety and tolerability of RenaZorb (also referred to as SPI-014) in healthy volunteers.
Aflac Incorporated announced today that Japan Post will be expanding the number of post offices selling Aflac cancer products to an additional 10,064 starting July 1, 2015, which will bring the total number of post offices selling Aflac cancer products to 20,076 throughout Japan.
"Almost every nation, regardless of its wealth and resources, faces a continuing shortage of nurses and an acute lack of nursing faculty available to educate more nurses. This dearth of practicing nurses and nurse educators is particularly critical in countries like Haiti and other developing high-risk, low-resourced nations," Martha Hill, dean of Johns Hopkins School of Nursing, writes in a Baltimore Sun opinion piece encouraging the expansion of global nursing.
› Verified 3 days ago
| Entity Name | Pratt Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275570319 PECOS PAC ID: 3375515661 Enrollment ID: O20040807000255 |
News Archive
Use of the targeted agent pacritinib significantly reduced the symptoms and burden of advanced myelofibrosis in patients, says a Mayo Clinic researcher who co-led PERSIST-1, the worldwide phase III clinical trial that tested the therapy. Specifically, pacritinib substantially reduced severe enlargement of the spleen, a typical feature of advanced myelofibrosis, in more than 20 percent of patients and alleviated debilitating side effects in more than 46 percent.
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced positive, statistically significant data from the Company's Phase 1 clinical trial evaluating the safety and tolerability of RenaZorb (also referred to as SPI-014) in healthy volunteers.
Aflac Incorporated announced today that Japan Post will be expanding the number of post offices selling Aflac cancer products to an additional 10,064 starting July 1, 2015, which will bring the total number of post offices selling Aflac cancer products to 20,076 throughout Japan.
"Almost every nation, regardless of its wealth and resources, faces a continuing shortage of nurses and an acute lack of nursing faculty available to educate more nurses. This dearth of practicing nurses and nurse educators is particularly critical in countries like Haiti and other developing high-risk, low-resourced nations," Martha Hill, dean of Johns Hopkins School of Nursing, writes in a Baltimore Sun opinion piece encouraging the expansion of global nursing.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Brian J Cohen, MD 750 Washington St, Boston, MA 02111-1526 Ph: (617) 636-5000 | Brian J Cohen, MD 750 Washington St, Boston, MA 02111-1526 Ph: (617) 636-5000 |
News Archive
Use of the targeted agent pacritinib significantly reduced the symptoms and burden of advanced myelofibrosis in patients, says a Mayo Clinic researcher who co-led PERSIST-1, the worldwide phase III clinical trial that tested the therapy. Specifically, pacritinib substantially reduced severe enlargement of the spleen, a typical feature of advanced myelofibrosis, in more than 20 percent of patients and alleviated debilitating side effects in more than 46 percent.
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced positive, statistically significant data from the Company's Phase 1 clinical trial evaluating the safety and tolerability of RenaZorb (also referred to as SPI-014) in healthy volunteers.
Aflac Incorporated announced today that Japan Post will be expanding the number of post offices selling Aflac cancer products to an additional 10,064 starting July 1, 2015, which will bring the total number of post offices selling Aflac cancer products to 20,076 throughout Japan.
"Almost every nation, regardless of its wealth and resources, faces a continuing shortage of nurses and an acute lack of nursing faculty available to educate more nurses. This dearth of practicing nurses and nurse educators is particularly critical in countries like Haiti and other developing high-risk, low-resourced nations," Martha Hill, dean of Johns Hopkins School of Nursing, writes in a Baltimore Sun opinion piece encouraging the expansion of global nursing.
› Verified 3 days ago
Kaitlyn My-tu Lam, MBBS Nephrology Medicare: Not Enrolled in Medicare Practice Location: Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114 Phone: 617-724-7738 | |
Kui Toh Gerard Leong, M.D. Nephrology Medicare: Not Enrolled in Medicare Practice Location: 55 Fruit Street, Massachusetts General Hospital, Boston, MA 02114 Phone: 617-726-8862 | |
Ruma Rajbhandari, Nephrology Medicare: Accepting Medicare Assignments Practice Location: 75 Francis St, Boston, MA 02115 Phone: 617-525-6841 | |
Alaka Ray, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114 Phone: 617-726-2066 | |
Meghan E Sise, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114 Phone: 617-726-2862 | |
Aaron Dickstein, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 800 Washington St, Box 233, Boston, MA 02111 Phone: 617-636-5883 Fax: 617-636-9292 | |
Dr. Felicia Elizabeth Patch, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 801 Massachusetts Ave, Crosstown 2, Boston, MA 02118 Phone: 617-414-4376 Fax: 617-414-4676 |